Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Brain Res ; 406: 113229, 2021 05 21.
Article in English | MEDLINE | ID: mdl-33684425

ABSTRACT

Increased neuroinflammation has been shown in individuals diagnosed with schizophrenia (SCHZ). This study evaluated a novel immune modulator (PD2024) that targets the pro-inflammatory cytokine tumor necrosis factor-alpha (TNFα) to alleviate sensorimotor gating deficits and microglial activation employing two different rodent models of SCHZ. In Experiment 1, rats were neonatally treated with saline or the dopamine D2-like agonist quinpirole (NQ; 1 mg/kg) from postnatal day (P) 1-21 which produces increases of dopamine D2 receptor sensitivity throughout the animal's lifetime. In Experiment 2, rats were neonatally treated with saline or the immune system stimulant polyinosinic:polycytidylic acid (Poly I:C) from P5-7. Neonatal Poly I:C treatment mimics immune system activation associated with SCHZ. In both experiments, rats were raised to P30 and administered a control diet or a novel TNFα inhibitor PD2024 (10 mg/kg) in the diet from P30 until P67. At P45-46 and from P60-67, animals were behaviorally tested on auditory sensorimotor gating as measured through prepulse inhibition (PPI). NQ or Poly I:C treatment resulted in PPI deficits, and PD2024 treatment alleviated PPI deficits in both models. Results also revealed that increased hippocampal and prefrontal cortex microglial activation produced by neonatal Poly I:C was significantly reduced to control levels by PD2024. In addition, a separate group of animals neonatally treated with saline or Poly I:C from P5-7 demonstrated increased TNFα protein levels in the hippocampus but not prefrontal cortex, verifying increased TNFα in the brain produced by Poly I:C. Results from this study suggests that that brain TNFα is a viable pharmacological target to treat the neuroinflammation known to be associated with SCHZ.


Subject(s)
Hippocampus/drug effects , Immunomodulating Agents/pharmacology , Microglia/drug effects , Neuroinflammatory Diseases/drug therapy , Prepulse Inhibition/drug effects , Schizophrenia/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Age Factors , Animals , Animals, Newborn , Behavior, Animal/drug effects , Disease Models, Animal , Dopamine Agonists/administration & dosage , Hippocampus/immunology , Hippocampus/metabolism , Hippocampus/physiopathology , Immunomodulating Agents/administration & dosage , Male , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/metabolism , Neuroinflammatory Diseases/physiopathology , Rats , Rats, Sprague-Dawley , Schizophrenia/immunology , Schizophrenia/metabolism , Schizophrenia/physiopathology
2.
J Neurotrauma ; 33(16): 1501-13, 2016 08 15.
Article in English | MEDLINE | ID: mdl-26530250

ABSTRACT

Diffuse axonal injury is recognized as a progressive and long-term consequence of traumatic brain injury. Axonal injury can have sustained negative consequences on neuronal functions such as anterograde and retrograde transport and cellular processes such as autophagy that depend on cytoarchitecture and axon integrity. These changes can lead to somatic atrophy and an inability to repair and promote plasticity. Obstruction of the autophagic process has been noted after brain injury, and rapamycin, a drug used to stimulate autophagy, has demonstrated positive effects in brain injury models. The optimization of drugs to promote beneficial autophagy without negative side effects could be used to attenuate traumatic brain injury and promote improved outcome. Lanthionine ketimine ethyl ester, a bioavailable derivative of a natural sulfur amino acid metabolite, has demonstrated effects on autophagy both in vitro and in vivo. Thirty minutes after a moderate central fluid percussion injury and throughout the survival period, lanthionine ketimine ethyl ester was administered, and mice were subsequently evaluated for learning and memory impairments and biochemical and histological changes over a 5-week period. Lanthionine ketimine ethyl ester, which we have shown previously to modulate autophagy markers and alleviate pathology and slow cognitive decline in the 3 × TgAD mouse model, spared cognition and pathology after central fluid percussion injury through a mechanism involving autophagy modulation.


Subject(s)
Amino Acids, Sulfur/pharmacology , Autophagy/drug effects , Diffuse Axonal Injury/drug therapy , Amino Acids, Sulfur/administration & dosage , Animals , Disease Models, Animal , Mice , Mice, Inbred C57BL
3.
PLoS One ; 10(10): e0137305, 2015.
Article in English | MEDLINE | ID: mdl-26436670

ABSTRACT

Cytokines such as TNFα can polarize microglia/macrophages into different neuroinflammatory types. Skewing of the phenotype towards a cytotoxic state is thought to impair phagocytosis and has been described in Alzheimer's Disease (AD). Neuroinflammation can be perpetuated by a cycle of increasing cytokine production and maintenance of a polarized activation state that contributes to AD progression. In this study, 3xTgAD mice, age 6 months, were treated orally with 3 doses of the TNFα modulating compound isoindolin-1,3 dithione (IDT) for 10 months. We demonstrate that IDT is a TNFα modulating compound both in vitro and in vivo. Following long-term IDT administration, mice were assessed for learning & memory and tissue and serum were collected for analysis. Results demonstrate that IDT is safe for long-term treatment and significantly improves learning and memory in the 3xTgAD mouse model. IDT significantly reduced paired helical filament tau and fibrillar amyloid accumulation. Flow cytometry of brain cell populations revealed that IDT increased the infiltrating neutrophil population while reducing TNFα expression in this population. IDT is a safe and effective TNFα and innate immune system modulator. Thus small molecule, orally bioavailable modulators are promising therapeutics for Alzheimer's disease.


Subject(s)
Alzheimer Disease/drug therapy , Cognition/classification , Isoindoles/administration & dosage , Isoindoles/pharmacology , Neutrophil Infiltration/drug effects , Thioamides/administration & dosage , Thioamides/pharmacology , Thiones/administration & dosage , Thiones/pharmacology , Tumor Necrosis Factor-alpha/metabolism , tau Proteins/chemistry , Administration, Oral , Alzheimer Disease/immunology , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Biological Availability , Brain/drug effects , Brain/immunology , Brain/metabolism , Brain/pathology , Cell Line , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Humans , Immunity, Innate/drug effects , Isoindoles/adverse effects , Isoindoles/therapeutic use , Macrophages/drug effects , Macrophages/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microglia/drug effects , Microglia/metabolism , Phenotype , Protein Multimerization/drug effects , Protein Structure, Secondary/drug effects , Safety , Solubility , Thioamides/adverse effects , Thioamides/therapeutic use , Thiones/adverse effects , Thiones/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors
4.
J Neuropathol Exp Neurol ; 72(10): 955-69, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24042198

ABSTRACT

Lanthionine ketimine ([LK] 3,4-dihydro-2H-1,4-thiazine-3,5-dicarboxylic acid) is the archetype for a family of naturally occurring brain sulfur amino acid metabolites, the physiologic function of which is unknown. Lanthionine ketimine and its synthetic derivatives have recently demonstrated neurotrophic, neuroprotective, and antineuroinflammatory properties in vitro through a proposed mechanism involving the microtubule-associated protein collapsin response mediator protein 2. Therefore, studies were undertaken to test the effects of a bioavailable LK ester in the 3 × Tg-AD mouse model of Alzheimer disease. Lanthionine ketimine ester treatment substantially diminished cognitive decline and brain amyloid-ß (Aß) peptide deposition and phospho-Tau accumulation in 3 × Tg-AD mice and also reduced the density of Iba1-positive microglia. Furthermore, LK ester treatment altered collapsin response mediator protein 2 phosphorylation. These findings suggest that LK may not be a metabolic waste but rather a purposeful neurochemical, the synthetic derivatives of which constitute a new class of experimental therapeutics for Alzheimer disease and related entities.


Subject(s)
Alzheimer Disease/drug therapy , Amino Acids, Sulfur/therapeutic use , Brain/drug effects , Cognition/drug effects , Maze Learning/drug effects , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Amino Acids, Sulfur/pharmacology , Animals , Behavior, Animal/drug effects , Brain/pathology , Cell Line, Tumor , Disease Models, Animal , Female , Male , Mice , Mice, Transgenic , Nesting Behavior/drug effects , Neurons/drug effects , Neurons/pathology , Phosphorylation/drug effects
5.
J Neuroinflammation ; 9: 99, 2012 May 25.
Article in English | MEDLINE | ID: mdl-22632257

ABSTRACT

BACKGROUND: Chronic neuroinflammation is an important component of Alzheimer's disease and could contribute to neuronal dysfunction, injury and loss that lead to disease progression. Multiple clinical studies implicate tumor necrosis factor-α as an inflammatory mediator of neurodegeneration in patients with Alzheimer's because of elevated levels of this cytokine in the cerebrospinal fluid, hippocampus and cortex. Current Alzheimer's disease interventions are symptomatic treatments with limited efficacy that do not address etiology. Thus, a critical need exists for novel treatments directed towards modifying the pathophysiology and progression. METHODS: To investigate the effect of early immune modulation on neuroinflammation and cognitive outcome, we treated triple transgenic Alzheimer's disease mice (harboring PS1(M146V), APP(Swe), and tau(P301L) transgenes) with the small molecule tumor necrosis factor-α inhibitors, 3,6'-dithiothalidomide and thalidomide, beginning at four months of age. At this young age, mice do not exhibit plaque or tau pathology but do show mild intraneuronal amyloid beta protein staining and a robust increase in tumor necrosis factor-α. After 10 weeks of treatment, cognitive performance was assessed using radial arm maze and neuroinflammation was assessed using biochemical, stereological and flow cytometric endpoints. RESULTS: 3,6'-dithiothalidomide reduced tumor necrosis factor-α mRNA and protein levels in the brain and improved working memory performance and the ratio of resting to reactive microglia in the hippocampus of triple transgenic mice. In comparison to non-transgenic controls, triple transgenic Alzheimer's disease mice had increased total numbers of infiltrating peripheral monomyelocytic/granulocytic leukocytes with enhanced intracytoplasmic tumor necrosis factor-α, which was reduced after treatment with 3,6'-dithiothalidomide. CONCLUSIONS: These results suggest that modulation of tumor necrosis factor-α with small molecule inhibitors is safe and effective with potential for the long-term prevention and treatment of Alzheimer's disease.


Subject(s)
Alzheimer Disease/drug therapy , Cognition Disorders/prevention & control , Disease Models, Animal , Neuroprotective Agents/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Animals , Cells, Cultured , Cognition Disorders/genetics , Cognition Disorders/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neuroprotective Agents/pharmacology , Thalidomide/analogs & derivatives , Thalidomide/pharmacology , Thalidomide/therapeutic use , Time Factors , Tumor Necrosis Factor-alpha/biosynthesis
6.
J Neurotrauma ; 22(1): 83-94, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15665604

ABSTRACT

Previous studies from our laboratory indicate that traumatic brain injury (TBI) in humans results in proteolysis of neuronally-localized, intracellular microtubule associated protein (MAP)-tau to produce cleaved tau (C-tau). The present study evaluated the utility of C-tau to function as a biomarker of neuronal injury and as a biomarker for evaluating neuroprotectant drug efficacy in a controlled cortical impact model of rat TBI. Brain C-tau was determined in rats subjected to controlled cortical impact-induced mild, moderate or severe levels of TBI. A significant severity-dependent increase in C-tau levels was observed in the cortex and hippocampus (1.5-8-fold) of TBI rats compared to shams 72 h after impact. C-tau rat brain and serum time course was determined by measuring levels at 0.25, 6, 24, 48, 72 and 168 h after TBI. A significant time-dependent increase in C-tau levels was observed in ipsilateral cortex (5-16-fold) and hippocampus (2-40-fold) compared to sham animals. C-tau levels increased as early as 6 h after TBI with peak C-tau levels observed 168 h after injury. Elevated brain C-tau levels were associated with TBI-induced tissue loss, which was histologically determined. The effect of cyclosporin-A (CsA), previously demonstrated to be neuroprotective in rat TBI, on brain C-tau levels was examined. CsA (20 mg/kg i.p., 15 min and 24 h after TBI) significantly attenuated the TBI-induced increase in hippocampal C-tau levels observed in vehicle-treated animals confirming CsA's neuroprotectant effect. CsA treatment also lowered ipsilateral cortical C-tau levels, although it did not reach statistical significance. CsA's neuroprotectant effect was confirmed utilizing histologic measures of TBI-induced tissue loss. In addition, serum C-tau levels were significantly increased 6 h after TBI but not at later time points. These results suggest that C-tau is a reliable, quantitative biomarker for evaluating TBI-induced neuronal injury and a potential biomarker of neuroprotectant drug efficacy in the rat TBI model. Serum data suggests that C-tau levels are dependent both on a compromised blood-brain barrier as well as release of TBI biomarkers from the brain, which has implications for the study of human serum TBI biomarkers.


Subject(s)
Brain Damage, Chronic/metabolism , Brain Injuries/metabolism , Cyclosporine/pharmacology , Neuroprotective Agents/pharmacology , tau Proteins/drug effects , tau Proteins/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain Damage, Chronic/etiology , Brain Damage, Chronic/pathology , Brain Injuries/complications , Brain Injuries/pathology , Disease Models, Animal , Male , Rats , Rats, Sprague-Dawley , Time Factors , Trauma Severity Indices
7.
J Neurochem ; 91(1): 133-43, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15379894

ABSTRACT

Familial forms of amyotrophic lateral sclerosis (ALS) can be caused by mutations in copper, zinc-superoxide dismutase (SOD1). Mice expressing SOD1 mutants demonstrate a robust neuroinflammatory reaction characterized, in part, by up-regulation of tumor necrosis factor alpha (TNFalpha) and its primary receptor TNF-RI. In an effort to identify small molecule inhibitors of neuroinflammation useful in treatment of ALS, a microglial culture system was established to identify TNFalpha antagonists. Walker EOC-20 microglia cells were stimulated with recombinant TNFalpha, with or without inhibitors, and the cell response was indexed by NO2- output. Three hundred and fifty-five rationally selected compounds were included in this bioassay. The arachidonic acid 5-lipoxygenase (5LOX) and tyrosine kinase inhibitor nordihydroguaiaretic acid (NDGA), a natural dicatechol, was one of the most potent non-cytotoxic antagonists tested (IC50 8 +/- 3 microm). Investigation of the G93A-SOD1 mouse model for ALS revealed increased message and protein levels of 5LOX at 120 days of age. Oral NDGA (2500 p.p.m.) significantly extended lifespan and slowed motor dysfunction in this mouse, when administration was begun relatively late in life (90 days). NDGA extended median total lifespan of G93A-SOD1 mice by 10%, and life expectancy following start of treatment was extended by 32%. Disease-associated gliosis and cleaved microtubule-associated tau protein, an indicator of axon damage, were likewise reduced by NDGA. Thus, TNFalpha antagonists and especially 5LOX inhibitors might offer new opportunities for treatment of ALS.


Subject(s)
Lipoxygenase Inhibitors , Lipoxygenase Inhibitors/pharmacology , Masoprocol/pharmacology , Microglia/drug effects , Paralysis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Administration, Oral , Age Factors , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Blotting, Northern/methods , Blotting, Western/methods , Body Mass Index , Cell Line , Curcumin/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay/methods , Glial Fibrillary Acidic Protein/metabolism , Humans , Immunohistochemistry/methods , Inhibitory Concentration 50 , Lipoxygenase Inhibitors/therapeutic use , Masoprocol/therapeutic use , Mice , Mice, Transgenic/physiology , Microglia/physiology , Models, Neurological , Motor Activity/drug effects , Nitric Oxide/metabolism , Paralysis/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Rotarod Performance Test/methods , Spinal Cord/cytology , Spinal Cord/drug effects , Spinal Cord/metabolism , Statistics, Nonparametric , Superoxide Dismutase/genetics , Superoxide Dismutase/physiology , Survival/physiology , Tumor Necrosis Factor-alpha/pharmacology , tau Proteins/metabolism
8.
Brain Res ; 947(1): 131-9, 2002 Aug 23.
Article in English | MEDLINE | ID: mdl-12144861

ABSTRACT

Following traumatic brain injury, the neuronally-localized intracellular protein MAP-tau is proteolytically cleaved (C-tau) and gains access to cerebrospinal fluid (CSF) and serum. The present study compared initial CSF C-tau levels, initial Glasgow Coma Scale (GCS) scores and elevated intracranial pressure (ICP) as predictors of clinical outcome. In this preliminary, prospective study of consecutive severe traumatic brain injured patients (TBI) clinical outcome was quantified with the Glasgow Outcome Scale (GOS) at discharge (n=28). Sensitivity and specificity of initial C-tau levels and initial GCS scores as predictors of clinical outcome is reported. To assess disease specificity C-tau levels were compared between TBI patients and neurologic (n=87) and non-neurologic control patients (n=67). Initial CSF C-tau levels were elevated 40,000 fold in TBI patients compared to either neurologic or non-neurologic control patients (P<0.001). Initial C-tau levels were correlated with clinical outcome (P=0.006) and were a significant predictor of dichotomized clinical outcome (P=0.011) demonstrating a sensitivity of prediction of 92% and a specificity of 94%. Initial C-tau levels were also a significant predictor of subsequent ICP with higher initial C-tau levels associated with elevated ICP (P=0.014). Initial GCS score were correlated with clinical outcome (P=0.026) and demonstrated a sensitivity of 50% and a specificity of 100% for predicting dichotomized clinical outcome. Statistical analysis indicated that initial C-tau levels and initial GCS scores were independent predictors of clinical outcome. The present preliminary study demonstrates that initial CSF C-tau levels are a significant predictor of ICP and clinical outcome with particular sensitivity for identifying severe TBI patients with good clinical outcome. Future studies employing a larger sample size and clinical outcome assessment at longer periods after hospitalization will be needed to determine the utility of initial C-tau levels as a clinical biomarker in TBI.


Subject(s)
Brain Injuries/metabolism , Brain Injuries/pathology , Intracranial Pressure/physiology , Neurons/pathology , tau Proteins/metabolism , Adolescent , Adult , Aged , Biomarkers , Brain Chemistry , Brain Injuries/physiopathology , Enzyme-Linked Immunosorbent Assay , Female , Glasgow Coma Scale , Humans , Immunoblotting , Male , Middle Aged , Predictive Value of Tests , Prognosis , Treatment Outcome , tau Proteins/cerebrospinal fluid
9.
Nitric Oxide ; 6(2): 221-7, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11890747

ABSTRACT

Oxidative stress and quasi-inflammatory processes recently have been recognized as contributing factors in the pathogenesis of Alzheimer's disease (AD). Reactive nitrating species have specifically been implicated in AD based on immunochemical and instrumental detection of nitrotyrosine in AD brain protein. The significance of lipid-phase nitration has not been investigated in AD. This study documents a significant two- to threefold increase in the lipid nitration product 5-nitro-gamma-tocopherol in affected regions of the AD brain as determined by high-performance liquid chromatography with electrochemical detection. In a bioassay to compare the relative potency of alpha-tocopherol and gamma-tocopherol against nitrative stress, rat brain mitochondria were exposed to the peroxynitrite-generating compound SIN-1. The oxidation-sensitive Kreb's cycle enzyme alpha-ketoglutarate dehydrogenase was inactivated by SIN-1, in a manner that could be significantly attenuated by gamma-tocopherol (at <10 microM) but not by alpha-tocopherol. These data indicate that nitric oxide-derived species are significant contributors to lipid oxidation in the AD brain. The findings are discussed in reference to the neuroinflammatory hypothesis of AD and the possible role of gamma-tocopherol as a major lipid-phase scavenger of reactive nitrogen species.


Subject(s)
Alzheimer Disease/metabolism , Brain/metabolism , Molsidomine/analogs & derivatives , Reactive Nitrogen Species/metabolism , gamma-Tocopherol/analogs & derivatives , gamma-Tocopherol/metabolism , gamma-Tocopherol/pharmacology , Aged , Aged, 80 and over , Antioxidants/pharmacology , Brain/cytology , Brain/pathology , Female , Humans , Ketoglutarate Dehydrogenase Complex/antagonists & inhibitors , Lipid Metabolism , Male , Mitochondria/metabolism , Molsidomine/pharmacology , Nitric Oxide Donors/pharmacology , Reactive Nitrogen Species/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...